PE20141061A1 - Compuesto inhibidor de la senalizacion de la trayectoria notch - Google Patents

Compuesto inhibidor de la senalizacion de la trayectoria notch

Info

Publication number
PE20141061A1
PE20141061A1 PE2014000129A PE2014000129A PE20141061A1 PE 20141061 A1 PE20141061 A1 PE 20141061A1 PE 2014000129 A PE2014000129 A PE 2014000129A PE 2014000129 A PE2014000129 A PE 2014000129A PE 20141061 A1 PE20141061 A1 PE 20141061A1
Authority
PE
Peru
Prior art keywords
trajectory
signaling
notch
inhibitor compound
theta
Prior art date
Application number
PE2014000129A
Other languages
English (en)
Inventor
Philip Arthur Hipskind
Gregory Alan Stephenson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20141061A1 publication Critical patent/PE20141061A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA (I) QUE SE CARACTERIZA PORQUE ES UN HIDRATO CRISTALINO QUE TIENE UN PATRON DE DIFRACCION EN POLVO DE RAYOS -X USANDO RADIACION CuK? QUE TIENE UN PICO A 22.97�0.2 GRADOS 2-THETA EN COMBINACION CON UNO O MAS PICOS A 18.81�0.2, 20.78�0.2, 21.07�0.2 GRADOS 2-THETA A TEMPERATURA AMBIENTE Y HUMEDAD RELATIVA. SE REFIERE TAMBIEN A UN COMPUESTO FARMACEUTICO, SIENDO UTIL PARA EL TRATAMIENTO DE CANCER.
PE2014000129A 2011-07-27 2012-07-18 Compuesto inhibidor de la senalizacion de la trayectoria notch PE20141061A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161512016P 2011-07-27 2011-07-27
US201161560486P 2011-11-16 2011-11-16

Publications (1)

Publication Number Publication Date
PE20141061A1 true PE20141061A1 (es) 2014-09-06

Family

ID=46598983

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014000129A PE20141061A1 (es) 2011-07-27 2012-07-18 Compuesto inhibidor de la senalizacion de la trayectoria notch

Country Status (36)

Country Link
US (1) US8569286B2 (es)
EP (1) EP2736920B1 (es)
JP (1) JP6027110B2 (es)
KR (1) KR101578309B1 (es)
CN (1) CN103732612B (es)
AP (1) AP4080A (es)
AR (1) AR087107A1 (es)
AU (1) AU2012287251B2 (es)
BR (1) BR112014001600B1 (es)
CA (1) CA2841178C (es)
CL (1) CL2014000175A1 (es)
CO (1) CO6862159A2 (es)
CR (1) CR20140036A (es)
CY (1) CY1116645T1 (es)
DK (1) DK2736920T3 (es)
DO (1) DOP2014000011A (es)
EA (1) EA023044B1 (es)
EC (1) ECSP14013179A (es)
ES (1) ES2544937T3 (es)
GT (1) GT201400012A (es)
HK (1) HK1194086A1 (es)
HR (1) HRP20150771T1 (es)
HU (1) HUE027534T2 (es)
IL (1) IL229988A (es)
JO (1) JO3148B1 (es)
MA (1) MA35611B1 (es)
ME (1) ME02171B (es)
MX (1) MX356536B (es)
MY (1) MY184303A (es)
PE (1) PE20141061A1 (es)
PL (1) PL2736920T3 (es)
PT (1) PT2736920E (es)
RS (1) RS54135B1 (es)
SI (1) SI2736920T1 (es)
TW (1) TWI568730B (es)
WO (1) WO2013016081A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10350216B2 (en) 2013-01-14 2019-07-16 The Trustees Of Columbia University In The City Of New York Methods of treating, preventing and diagnosing leukemia and other blood diseases and disorders
KR20160099081A (ko) 2013-07-26 2016-08-19 업데이트 파마 인코포레이트 비산트렌의 치료 효과 개선용 조합 방법
TWI704151B (zh) 2014-12-22 2020-09-11 美商美國禮來大藥廠 Ｅｒｋ抑制劑
TWI609687B (zh) 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
JO3491B1 (ar) * 2015-07-07 2020-07-05 Audion Therapeutics مركبات مثبطة لإشارات مسار notch
CR20180413A (es) 2016-02-05 2018-12-04 Denali Therapeutics Inc Inhibidores de la proteína quinasa 1 que interactua con el receptor
AU2017233898B2 (en) 2016-03-15 2022-12-15 Oryzon Genomics, S.A. Combinations of LSD1 inhibitors for use in the treatment of solid tumors
KR102418765B1 (ko) * 2016-04-12 2022-07-08 일라이 릴리 앤드 캄파니 암 치료를 위한 Notch 및 CDK4/6 억제제의 조합 요법
CA3020918A1 (en) * 2016-04-12 2017-10-19 Eli Lilly And Company Combination therapy with notch and pi3k/mtor inhibitors for use in treating cancer
WO2017200969A1 (en) * 2016-05-20 2017-11-23 Eli Lilly And Company Combination therapy with notch and pd-1 or pd-l1 inhibitors
MA46086A (fr) 2016-08-31 2019-07-10 Lilly Co Eli Schéma posologique pour le traitement de tumeurs solides
CA3039405A1 (en) 2016-10-12 2018-04-19 Eli Lilly And Company Targeted treatment of mature t-cell lymphoma
WO2018107060A1 (en) 2016-12-09 2018-06-14 Denali Therapeutics Inc. Compounds, compositions and methods
ES2949364T3 (es) 2017-02-17 2023-09-28 Fred Hutchinson Cancer Center Terapias de combinación para el tratamiento de cánceres y trastornos autoinmunitarios relacionados con BCMA
US11066475B2 (en) 2017-11-01 2021-07-20 Juno Therapeutics, Inc. Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides
AU2018359907A1 (en) * 2017-11-06 2020-05-07 Fred Hutchinson Cancer Center Combination of a cell therapy and a gamma secretase inhibitor
MX2020011826A (es) * 2018-05-06 2021-01-15 Ayala Pharmaceuticals Inc Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas.
TW202034900A (zh) 2018-10-02 2020-10-01 美商頻率醫療公司 有關耳用治療劑之醫藥組成物及方法
MA55611A (fr) 2019-04-08 2022-02-16 Frequency Therapeutics Inc Association de chir99021 et d'acide valproïque pour traiter une perte auditive

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ335583A (en) * 1996-12-23 2001-03-30 Lilly Co Eli Cycloalkyl, lactam, lactone and analogs, and pharmaceutical compositions
WO1999067219A1 (en) 1998-06-22 1999-12-29 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
CA2325389A1 (en) * 1998-06-22 1999-12-29 James E. Audia Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
ES2311795T3 (es) 2003-02-04 2009-02-16 F. Hoffmann-La Roche Ag Derivados de malonamida como inhibidores de gamma-secretasa.
KR20070087233A (ko) 2003-09-09 2007-08-27 에프. 호프만-라 로슈 아게 감마-세크리테이즈의 활성을 차단하는 말론아미드 유도체
US7166587B2 (en) 2003-10-06 2007-01-23 Hoffmann-La Roche Inc. Carbamic acid alkyl ester derivatives
RU2440342C2 (ru) 2006-03-27 2012-01-20 Ф.Хоффманн-Ля Рош Аг МАЛОНАМИДНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ γ-СЕКРЕТАЗЫ
AU2008209861B2 (en) * 2007-02-02 2012-08-09 F. Hoffmann-La Roche Ag 6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl derivatives
EP2244713A1 (en) 2008-01-11 2010-11-03 F. Hoffmann-La Roche AG Use of a gamma-secretase inhibitor for treating cancer
WO2011060051A1 (en) * 2009-11-12 2011-05-19 University Of Massachusetts Methods for treating glioblastoma

Also Published As

Publication number Publication date
CY1116645T1 (el) 2017-03-15
EP2736920A1 (en) 2014-06-04
PT2736920E (pt) 2015-09-16
CN103732612B (zh) 2015-09-23
JP6027110B2 (ja) 2016-11-16
US8569286B2 (en) 2013-10-29
ES2544937T3 (es) 2015-09-07
TW201315732A (zh) 2013-04-16
CN103732612A (zh) 2014-04-16
AP4080A (en) 2017-03-29
TWI568730B (zh) 2017-02-01
CR20140036A (es) 2014-03-21
MX2014001084A (es) 2014-02-27
JP2014527042A (ja) 2014-10-09
US20130029972A1 (en) 2013-01-31
DOP2014000011A (es) 2014-07-31
EP2736920B1 (en) 2015-07-01
IL229988A (en) 2017-07-31
GT201400012A (es) 2014-07-16
AR087107A1 (es) 2014-02-12
EA201490161A1 (ru) 2014-04-30
HRP20150771T1 (hr) 2015-08-28
ECSP14013179A (es) 2014-03-31
MY184303A (en) 2021-03-31
HUE027534T2 (en) 2016-11-28
JO3148B1 (ar) 2017-09-20
MA35611B1 (fr) 2014-11-01
NZ618891A (en) 2015-12-24
KR20140026624A (ko) 2014-03-05
CO6862159A2 (es) 2014-02-10
CA2841178C (en) 2016-12-20
CA2841178A1 (en) 2013-01-31
EA023044B1 (ru) 2016-04-29
CL2014000175A1 (es) 2014-08-22
SI2736920T1 (sl) 2015-08-31
BR112014001600B1 (pt) 2022-09-13
BR112014001600A2 (pt) 2017-02-21
MX356536B (es) 2018-06-01
PL2736920T3 (pl) 2015-11-30
AU2012287251B2 (en) 2015-05-14
RS54135B1 (en) 2015-12-31
AP2014007362A0 (en) 2014-01-31
DK2736920T3 (en) 2015-07-20
WO2013016081A1 (en) 2013-01-31
AU2012287251A1 (en) 2014-01-30
KR101578309B1 (ko) 2015-12-16
ME02171B (me) 2015-10-20
HK1194086A1 (en) 2014-10-10

Similar Documents

Publication Publication Date Title
PE20141061A1 (es) Compuesto inhibidor de la senalizacion de la trayectoria notch
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
CY1119585T1 (el) Ενωσεις τετραϋδροπυρρολοθειαζινης
PH12015501058A1 (en) Pyrimidine-2,4-diamine derivatives for treatment of cancer
AR090253A1 (es) Formas polimorficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluor-3-fenilquinazolin-4(3h)-ona
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
PH12016500169A1 (en) Polymorph of syk inhibitors
CL2012001627A1 (es) Compuestos derivados de 1,3-tiazol-fenilaminopirimidinas, inhibidores de syk; composición farmacéutica; y su uso para el tratamiento de la artritis reumatoide y cancer.
MX2021014531A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
EA201491456A1 (ru) Соединения-ингибиторы raf
EA201591913A1 (ru) Ингибиторы протеинкиназы
BR112015000399A2 (pt) derivados de pirazolil pirimidina
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
UA113470C2 (xx) Піримідинові та піридинові сполуки та їх застосування
MX2016006432A (es) Tetrahidro-benzodiazepinonas.
AR080490A1 (es) FORMAS CRISTALINAS DE UN INHIBIDOR DE ELASTASA NEUTROFILA, COMPOSICIoN FARMACEUTICA QUE LAS COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE LA DEFICIENCIA DE ALFA-1-ANTITRIPSINA
CL2015002027A1 (es) Compuestos quimicos
MX351863B (es) Compuesto de anillo fusionado quinolilpirrolopirimidilo o sal del mismo.
RS54716B1 (en) HETEROCYCLIC COMPOUNDS AND THEIR APPLICATIONS
MX2015016332A (es) Inhibidores de alk biciclicos fusionados.
WO2015070238A3 (en) Coumarin based hsp90 inhibitors with urea and ether substituents
AR075418A1 (es) Polimorfo cristalino de 3-{[5-(azetidin-1-ilcarbonil)pirazin-2-il]oxi}-5-{[(1s)-1-metil-2-(metiloxi)etil]oxi}-n-(5-metilpirazin-2-il)benzamida,composiciones farmaceuticas que los contienen, proceso para prepararla y uso de las mismas para el tratamiento de la diabetes tipo ii y/u obesidad.
PH12016500735A1 (en) Substituted pyrimidine compounds and their use as syk inhibitors
MX2016007985A (es) Compuestos de fluorofenilpirazol.
BR112015023351A2 (pt) forma cristalina de sovaprevir, composição farmacêutica, e, método para tratar um distúrbio

Legal Events

Date Code Title Description
FG Grant, registration